Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions
Pharmacist-focused review synthesizes existing semaglutide obesity evidence, noting efficacy with ongoing safety monitoring needs.
This narrative review synthesized 34 studies on semaglutide for obesity management, noting consistent weight reduction efficacy, mixed signals on suicidal ideation risk, limited pancreatitis evidence, and evolving perioperative guidance. The review adds no new primary data but provides a pharmacist-focused synthesis of current evidence on safety and adherence monitoring.
What the study was
- Study design
- Narrative review
- Population
- Patients receiving semaglutide for obesity; review from 1525 records → 34 included
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Journal of the American Pharmacists Association
Why it surfaced
Narrative review without meta-analysis; adds no new primary data; pharmacist-focused synthesis; JAPhA target audience limits research-pipeline value.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.